Microba Q4 FY26 slides: core testing surges 78%, breakeven eyed

Microba reported FY26 core testing volume up 78% to ~22,000 units and core testing revenue up 92% to $8.2m, with Q4 volume reaching 6,300 (+54% y/y) and an annualized run rate >25,000 tests. Management guided toward full-group cash-flow breakeven by calendar 2027 and is funding the plan via an institutional placement/share purchase plan at $0.05 (one free option, $0.0625 strike over 3 years), with the stock still near 52-week lows around $0.04 amid investor concern over cash burn. While early traction is strong (43 enterprise accounts in Australia generating 5,600+ tests), execution risk on profitability and the upcoming Q1 FY27 (Sep 2026) GI Navigator launch remain key catalysts.

Analysis

This is still a financing story disguised as a growth story. The key market mechanism is whether top-line scaling can outrun fixed-cost absorption before another dilution event; until that is proven, the equity should trade more like a cash-burn call option than a diagnostic platform multiple. The embedded free option in the placement terms may actually suppress near-term rerating because investors can wait for proof rather than pay up front.

The consensus is likely overemphasizing headline volume acceleration and underestimating how fragile the conversion curve can be in a niche clinical workflow. The real winner, if adoption sticks, is the channel network around the tests: lab partners and shareholder-distributors get incremental sample flow without funding the product development burden, while smaller competitors risk being boxed out if enterprise account economics keep improving. But if clinician orders per account stall, the growth algorithm breaks quickly and the market will reprice the name back toward liquidation math.

Catalysts are tight: the next 1-3 months are about whether the raise clears and whether the product launch lands with enough initial order density to justify the 2027 breakeven narrative. Over 6-18 months, the thesis lives or dies on cash burn trajectory and whether therapeutic partnering produces non-dilutive value. Falsifiers are simple: another equity raise before year-end, launch uptake below management's implied ramp, or evidence that volume growth is concentrated in a few accounts rather than broad-based. There is no credible TSM read-through here; this is idiosyncratic microcap execution risk, not AI-capex spillover.

Key Decisions for Investors

• Do not chase MCRB before the capital raise is fully absorbed; treat $0.04-$0.05 as a financing zone, not a fundamental entry point. Use a break back above the offer price with heavier volume as the first signal that dilution is out of the stock.
• If you want a tactical long, wait for the first GI Navigator commercial print in Q1 FY27 and only enter if it shows sustained account-level productivity, not just one-off launch orders. Upside is 30-50% on a credible de-risking; downside is another financing round if adoption disappoints.
• Use any post-raise strength in MCRB to fade into: the stock likely needs at least one more quarter of cash-burn improvement before it deserves a rerate. Falsifier for the short-bias is a clear step-up in clinician productivity plus management guidance removing the need for additional capital.
• Do not assign much standalone value to SKHHY from this story; any benefit is second-order and too small to move the needle. If you already own SKHHY for defensive healthcare exposure, keep it as a passive beneficiary rather than adding on the Microba narrative.
• Set an alert on any announcement of a strategic therapeutics partnership or upfront cash payment; that is the only near-term event that could reframe MCRB from dilution risk to platform monetization.